Patients with indolent SM have quality of life comparable to that of some cancers
Patients with indolent systemic mastocytosis appear to have a quality of life comparable to that of patients with lymphoma and leukemia
Patients with indolent systemic mastocytosis appear to have a quality of life comparable to that of patients with lymphoma and leukemia
A clinical trial demonstrated that bezuclastinib significantly improved symptoms and biomarkers of systemic mastocytosis.
Ultrasensitive duplex sequencing could improve diagnosis of indolent systemic mastocytosis in patients with low variant allele frequencies.
Patients with systemic mastocytosis (SM) showed promising overall response rates to treatment with bezuclastinib, its maker announced.
Some medical specialists lack awareness of systemic mastocytosis (SM) because of its association with various symptoms.
Patients with systemic mastocytosis (SM) have a different plasma protein profile compared to healthy people.
Preliminary results showed that patients receiving bezuclastinib had better results than patients receiving a placebo in a clinical trial.
A new study will examine a treatment for patients with systemic mastocytosis with an associated hematologic neoplasm.
Imatinib is a treatment for patients with aggressive SM without the KIT D816V mutation or having unknown KIT mutational status.
A new prognostic score confirmed that KIT Inhibitors improve outcomes in patients with advanced systemic mastocytosis (SM).